Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 28Rectal Neoplasms 6Colonic Neoplasms 6Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Neutropenia 2Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Advanced Solid Tumors 2mCRC 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Sarcoma, Ewing 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Microsatellite-stable Colorectal Cancer 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1High-grade Extra Pulmonary Neuroendocrine Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

Oxaliplatin 66pembrolizumab 47Fluorouracil 44Capecitabine 39Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 20Docetaxel 19Cisplatin 18S 1 (combination) 17Bevacizumab 15Irinotecan 14Drug Therapy 14tislelizumab 12Ramucirumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10sintilimab 9Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8atezolizumab 8Specimen Handling 8Biopsy 8durvalumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Stomach Neoplasms × trifluridine tipiracil drug combination × 1 year × Clear all
NCT06346392 2026-05-27

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Active not recruiting
592 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03686488 2026-03-02

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
23 enrolled 12 charts
Gastrointestinal

Stomach Neoplasms

NCT07212933 2025-10-08

RAK in GC

Chinese PLA General Hospital

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡